1.1
Teclistamab is recommended as an option for treating relapsed and refractory multiple myeloma in adults after 3 or more treatments (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on their last treatment. It is only recommended if:
the company provides teclistamab according to the commercial arrangement (see section 2).
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation